Teva introduces dexmethylphenidate hydrochloride capsules
NORTH WALES, Pa. — Teva Pharmaceuticals on Wednesday announced the introduction and availability of dexmethylphenidate hydrochloride extended-release capsules, CII, in 15-mg and 30-mg strengths. This product is AB rated and bioequivalent to Focalin XR extended-release capsules, CII.
With the addition of these two new strengths, Teva now offers dexmethylphenidate HCl extended-release capsules, CII in 15-mg, 30-mg and 40-mg.
"Our customers count on Teva for a continuous supply of new generic products,” stated Maureen Cavanaugh, SVP U.S. generics sales and marketing. "We are pleased to offer these two new strengths of Dexmethylphenidate HCl Extended-Release Capsules to our customers and patients."
CRN sets record straight on creatine
WASHINGTON — The Council for Responsible Nutrition on Wednesday refuted any possible link between use of creatine and the recent killings in Santa Barbara, Calif.
“Some media reports have inappropriately attempted to link the use of creatine to this tragedy. Those reports have been followed by other media stories disputing that possibility, noting that the original source fabricated his relationship to the shooter. We are responding to the science surrounding creatine," stated Duffy MacKay, SVP scientific and regulatory affairs, CRN.
"These are the facts on creatine: Creatine is a popular dietary supplement for athletes, particularly weight lifters and sprinters, because of its ability to extend the time it takes to reach muscle fatigue," MacKay said. "Creatine is also one of the most studied sports performance supplements, with more than 70 randomized controlled trials examining its effects. Creatine is not an anabolic steroid, nor is it a hormone. There is no reason to believe that using creatine would lead to psychological changes or side effects, to addiction or dependence, or to other safety risks."
MacKay concluded, "We extend our sympathies to the families and friends who lost their loved ones, and we regret having to step into the story. We urge the press to more carefully check their facts and more cautiously rely on their sources.”
Actavis to expand Puerto Rico operations
MANATI, Puerto Rico — Gov. Alejandro García Padilla on Wednesday announced an agreement by Puerto Rico Industrial Development Co. with Actavis that will allow the pharmaceutical manufacturer to develop a solid dosage manufacturing and packing facility in its Manati site and expand its current hormone production in Fajardo.
Actavis is investing $48 million and has committed to create up to 300 new jobs over a 36-month period, of which it already has created 100. This is happening in less than eight months after Actavis acquired global operations of Warner Chilcott, including the Manati and Fajardo plants. All plans should be completed by 2016.
PRIDCo is promoting Actavis expansion with incentives for job creation and infrastructure, among other benefits provided under the Economic Incentives for Development Act.
“This is a significant increase in production and jobs of a company that already is contributing close to $78 million a year to Puerto Rico’s economy, between salaries, income taxes and purchases to suppliers”, stated García Padilla while visiting the Manati site, on the northern region of Puerto Rico.